The global mRNA therapeutics market was valued at USD 8.91 billion in 2024 and is projected to be worth USD 6.01 billion in 2025, eventually reaching USD 21.45 billion by 2032. This represents a compound annual growth rate (CAGR) of 19.9% over the forecast period. In 2024, North America led the mRNA therapeutics market, accounting for a market share of 35.12%.
The mRNA therapeutics market is witnessing significant growth, primarily driven by the success of mRNA-based vaccines and expanding research into broader therapeutic applications. Prophylactic vaccines continue to dominate due to existing approvals and high global demand, while the drugs segment is rapidly advancing with a strong pipeline targeting cancer and genetic disorders. Infectious diseases remain the leading application area, though oncology is emerging as a major focus for future development. Distribution through hospital pharmacies remains dominant, supported by professional administration needs, while retail pharmacies are gaining momentum through enhanced accessibility and supportive health policies.
Continue reading for more details:
https://www.fortunebusinessinsights.com/mrna-therapeutics-market-113411
Market Segmentation
By product type, the mRNA Therapeutics Market is segmented into prophylactic vaccines and therapeutic vaccines.
By application, the market covers infectious diseases, oncology, rare genetic diseases, and other therapeutic areas.
Based on delivery method, the mRNA Therapeutics Market includes lipid nanoparticles, cationic nanoemulsions, and polymer-based carriers.
By end user, the market serves hospitals, specialty clinics, research laboratories, and contract manufacturing organizations.
List Of Key mRNA therapeutics Market Companies Profiled:
Moderna Inc. (U.S.)
BioNTech (Germany)
Pfizer Inc. (U.S.)
CureVac SE (Germany)
GSK plc. (U.K.)
Sanofi (France)
Omega Therapeutics (U.S.)
Strand Therapeutics (U.S.)
Immunomic Therapeutics (U.S.)
Market Growth
The mRNA Therapeutics Market is witnessing strong growth driven by advancements in genetic research and increased adoption of mRNA-based vaccines and therapies.
Rising prevalence of infectious diseases, cancers, and rare genetic disorders is fueling demand for the mRNA Therapeutics Market.
Technological innovations in lipid nanoparticle delivery systems are enhancing the stability and effectiveness of mRNA therapeutics.
Expanding applications beyond vaccines, including protein replacement therapy and regenerative medicine, are contributing to mRNA Therapeutics Market expansion.
Restraining Factors
High development and manufacturing costs are a major restraint in the mRNA therapeutics market.
Cold chain storage and transportation requirements limit accessibility, especially in low-resource settings.
Limited long-term safety data for newer mRNA therapies may affect regulatory approvals and public confidence.
Complex regulatory environments can delay the commercialization of mRNA therapeutics.
Challenges related to delivery systems and immune response modulation remain critical hurdles in the mRNA therapeutics market.
Regional Analysis
North America dominates the mRNA Therapeutics Market due to advanced biotechnology capabilities, strong R&D funding, and early adoption of innovative therapies.
Europe shows significant growth supported by government-backed vaccine initiatives and clinical research programs.
Asia Pacific is the fastest-growing region in the mRNA Therapeutics Market due to increasing healthcare investments, biotechnology partnerships, and rising disease burden.
Latin America is gradually expanding its mRNA capabilities through collaborations with global pharmaceutical firms.
Middle East & Africa presents emerging opportunities with growing interest in biotechnology and infectious disease prevention programs.